Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.64 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.62 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | CKS1B | P61024 | 1/20 | 0.53 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22922181 | 0.88 | CYP4F2 (0.59) | CYP4A11CYP4F2MAPTALDH1A1HSD17B10 | |
| SCHEMBL13056795 | 0.88 | CYP4A11 (0.50) | CYP4A11CYP4F2LOXL2MAPTALDH1A1 | |
| Methyl 3-Phenylpropanoate SCHEMBL8220307 | 0.88 | TSHR (0.63) | CYP4A11CYP4F2MAPTALDH1A1HPGD | |
| SCHEMBL1643935 | 0.87 | CYP4A11 (0.66) | CYP4A11CYP4F2LOXL2MAPTALDH1A1 | |
| SCHEMBL19889904 | 0.86 | CYP4A11 (0.69) | CYP4A11CYP4F2LOXL2MAPTALDH1A1 | |
| SCHEMBL70185 | 0.86 | CYP4A11 (0.75) | CYP4A11CYP4F2LOXL2MAPTALDH1A1 | |
| SCHEMBL2570247 | 0.85 | ALDH1A1 (0.52) | CYP4A11CYP4F2MAPTALDH1A1CA1 | |
| SCHEMBL168858 | 0.85 | KMT2A (0.59) | CYP4A11CYP4F2MAPTALDH1A1HSD17B10 | |
| SCHEMBL1629577 | 0.85 | CYP4A11 (0.64) | CYP4A11CYP4F2LOXL2MAPTALDH1A1 | |
| SCHEMBL661620 | 0.85 | CYP4A11 (0.64) | CYP4A11CYP4F2LOXL2MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111606883-B | Sulfur-containing compound based on glutarimide skeleton and application thereof | 上海科技大学 | 2023-05-09 | — | — | CN | disclosed |
| US-20230096517-A1 | GLUTARIMIDE SKELETON-BASED COMPOUNDS AND APPLICATION THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2023-03-30 | — | — | US | disclosed |
| EP-4112614-A1 | GLUTARIMIDE SKELETON-BASED COMPOUNDS AND APPLICATION THEREOF | Shanghaitech University (CN) | 2023-01-04 | — | — | EP | disclosed |
| US-20220143002-A1 | SULFUR-CONTAINING COMPOUND BASED ON GLUTARIMIDE SKELETON AND APPLICATION THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2022-05-12 | — | — | US | disclosed |
| US-20210355079-A1 | PRODRUGS OF HYDROXAMATE-BASED GCPII INHIBITORS | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I. (CZ) | 2021-11-18 | — | — | US | disclosed |
| CN-111606883-A | Sulfur-containing compound based on glutarimide framework and application thereof | 上海科技大学 | 2020-09-01 | — | — | CN | disclosed |
| WO-2018094334-A1 | PRODRUGS OF HYDROXAMATE-BASED GCPII INHIBITORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-05-24 | — | — | WO | disclosed |
| US-8030489-B2 | Ornithine derivative | ASTELLAS PHARMA INC. (JP) | 2011-10-04 | — | — | US | disclosed |
| US-20100216803-A1 | ORNITHINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-08-26 | — | — | US | disclosed |
| US-20100168101-A1 | OXINDOLE HYDRAZIDE MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2010-07-01 | — | — | US | disclosed |
| CN-1213019-C | Sulfonamide and carboxamide derivatives and drugs containing same as active ingredient | ONO PHARMACEUTICAL CO (JP) | 2005-08-03 | — | — | CN | disclosed |
| US-20050043388-A1 | Oxindole hydrazide modulators of protein tyrosine phosphatases (ptps) | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. | 2005-02-24 | — | — | US | disclosed |
| US-6790866-B2 | SUCH AS 4-(2-PHENYLSULFONYLAMINO-5-CHLOROBENZOYLAMINO)BENZOIC ACID FOR USE AS PROSTAGLANDIN E2 ANTAGONIST OR AGONIST; FOR INHIBITION OF UTERINE CONTRACTION, ANALGESICS, ANTIDIARRHEALS, SLEEP INDUCERS, AND/OR FOR INCREASE OF VESICAL CAPACITY | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-09-14 | — | — | US | disclosed |
| EP-1439834-A1 | OXINDOLE HYDRAZIDE MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) | Applied Research Systems ARS Holding N.V. (AN) | 2004-07-28 | — | — | EP | disclosed |
| WO-2003037328-A1 | OXINDOLE HYDRAZIDE MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2003-05-08 | — | — | WO | disclosed |
| US-20030060460-A1 | Such as 4-(2-phenylsulfonylamino-5-chlorobenzoylamino)benzoic acid for use as prostaglandin E2 antagonist or agonist; for inhibition of uterine contraction, analgesics, antidiarrheals, sleep inducers, and/or for increase of vesical capacity | OHUCHIDA SHUICHI (JP) | 2003-03-27 | — | — | US | disclosed |
| US-6448290-B1 | PROSTAGLANDIN E2 ANTAGONIST OR AGONIST; INHIBITION OF UTERINE CONTRACTION, ANALGESICS, ANTIDIARRHEALS, SLEEP INDUCERS, INCREASING VESICAL CAPACITY, CATHARTIC, SUPPRESSION OF GASTRIC ACID SECRETION, ANTIHYPERTENSIVE, DIURETIC AGENTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-09-10 | — | — | US | disclosed |
| US-6294573-B1 | FOR THERAPY RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, OSTEOPENIAS SUCH AS OSTEOPOROSIS, PERIODONTITIS, GINGIVITIS, CORNEAL, EPIDERMAL OR GASTRIC ULCERATION, AND TUMOR GROWTH AND METASTASIS OR INVASION | ABBOTT LABORATORIES | 2001-09-25 | — | — | US | disclosed |
| CN-1247529-A | Sulfonamide and carboxamide derivatives and drugs containing same as active ingredient | ONO PHARMACEUTICAL CO (JP) | 2000-03-15 | — | — | CN | disclosed |
| EP-0947500-A1 | SULFONAMIDE AND CARBOXAMIDE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 1999-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230096517-A1 | GLUTARIMIDE SKELETON-BASED COMPOUNDS AND APPLICATION THEREOF | GLS, GCDH, GLS2 | CYP4A11 571/4885CYP4F2 872/4885LOXL2 1231/4885 |
| US-20100216803-A1 | ORNITHINE DERIVATIVE | PTGER4, OXER1, ODC1 | CYP4A11 946/4885CYP4F2 2615/4885LOXL2 404/4885 |
| US-20210355079-A1 | PRODRUGS OF HYDROXAMATE-BASED GCPII INHIBITORS | TPI1, HPGDS, GPI | CYP4A11 2515/4885CYP4F2 1219/4885LOXL2 1853/4885 |
| US-20050043388-A1 | Oxindole hydrazide modulators of protein tyrosine phosphatases (ptps) | PTPRO, PTPRE, PTPRZ1 | CYP4A11 630/4885CYP4F2 941/4885LOXL2 2438/4885 |
| US-20100168101-A1 | OXINDOLE HYDRAZIDE MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) | PTPRO, PTPRE, PTPRZ1 | CYP4A11 636/4885CYP4F2 967/4885LOXL2 2420/4885 |
| US-20220143002-A1 | SULFUR-CONTAINING COMPOUND BASED ON GLUTARIMIDE SKELETON AND APPLICATION THEREOF | GLS, SQOR, GCDH | CYP4A11 428/4885CYP4F2 882/4885LOXL2 1793/4885 |
| US-20030060460-A1 | Such as 4-(2-phenylsulfonylamino-5-chlorobenzoylamino)benzoic acid for use as prostaglandin E2 antagonist or agonist; for inhibition of uterine contraction, analgesics, antidiarrheals, sleep inducers, and/or for increase of vesical capacity | CNR1, HCAR1, HCAR2 | CYP4A11 139/4885CYP4F2 356/4885LOXL2 1518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.